Heightened scrutiny of SEC disclosures regarding the drug development process has left some companies and their executives in the crosshairs of the SEC and shareholders. In a March 2015 speech, the SEC’s Enforcement Director stated, “accuracy of reporting in your dealings with the FDA is critical to getting investors the information they need. FDA dealings and approvals are the lifeblood of your business and are so important to investment See more +

Heightened scrutiny of SEC disclosures regarding the drug development process has left some companies and their executives in the crosshairs of the SEC and shareholders. In a March 2015 speech, the SEC’s Enforcement Director stated, “accuracy of reporting in your dealings with the FDA is critical to getting investors the information they need. FDA dealings and approvals are the lifeblood of your business and are so important to investment decisions.”

Pepper Hamilton attorneys Aline Fairweather, Scott R. Jones, Sharon R. Klein and Pamela S. Palmer discussed the recent uptick in SEC enforcement actions and shareholder lawsuits premised on misrepresentations or omissions regarding the drug development process and the specific types of disclosures that are garnering heightened scrutiny during this webinar as part of the Pepper Hamilton Health Sciences Speaker Series.

This is a video of the webinar.

See less -